Clinical Trial Update: Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy. [Phase 1]

View source ↗

Summary

This Phase 1 trial is evaluating the safety and feasibility of combining Y-90 radioembolization with stereotactic body radiation therapy for liver cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer

Drugs mentioned

• yttrium-90 radioembolization (Y-90 SIRT) (yttrium-90)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Liver Malignancy | Phase 1 | Status: RECRUITING